Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients

Parental prostacyclin is the only therapy with a proven survival benefit in pulmonary arterial hypertension (PAH). However, some patients are unable to tolerate continuous prostacyclin infusion because of central line infection, side effects, or sociocultural factors. Selexipag is a recently approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Holthaus, Nathan, Prins, Kurt W., Rose, Lauren, Prisco, Sasha, Pritzker, Marc, Thenappan, Thenappan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681254/
https://www.ncbi.nlm.nih.gov/pubmed/31215322
http://dx.doi.org/10.1177/2045894019862167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681254/
https://www.ncbi.nlm.nih.gov/pubmed/31215322
http://dx.doi.org/10.1177/2045894019862167

Ejemplares similares